risankizumab
abbvie
[' psa']
 et al: psa pts who were mda, dapsa lda, or acr50 responders vs non-responders reported clinically meaningful improvements across pros including pain, physical function, fatigue, and work productivity. abs 1019 #acr22 
Passionately curious rheumatologist, world traveler, wife, mother, sister, daughter, friend, dog lover. Believer in scientific method & evidence based medicine.